Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
As of today (2026-08-20), Lepu Scientech Medical Technology (Shanghai) Co's weighted average cost of capital is 5.01%%. Lepu Scientech Medical Technology (Shanghai) Co's ROIC % is 28.89% (calculated using TTM income statement data).
Lepu Scientech Medical Technology (Shanghai) Co generates higher returns on investment than it costs the company to raise the capital needed for that investment. It is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases.
For a comprehensive WACC calculation, please access the WACC Calculator.
Lepu Scientech Medical Technology (Shanghai) Co (HKSE:02291) WACC % Explanation
Because it costs money to raise capital. A firm that generates higher ROIC % than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.
As of today, Lepu Scientech Medical Technology (Shanghai) Co's weighted average cost of capital is 5.01%%. Lepu Scientech Medical Technology (Shanghai) Co's ROIC % is 28.89% (calculated using TTM income statement data).
Lepu Scientech Medical Technology (Shanghai) Co generates higher returns on investment than it costs the company to raise the capital needed for that investment. It is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases.
Be Aware
1. GuruFocus uses book value of debt (D) to do the calculation. It is simplified by adding latest one-year semi-annual average Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation together.
For companies that report quarterly, GuruFocus combines all of the most recent year's quarterly debt data from the beginning of the year to the year-end and calculates the average.
For companies that report semi-annually, GuruFocus combines all of the most recent year's semi-annual debt data from the start of the year to the year-end and calculates the average.
For companies that report annually, GuruFocus combines the beginning and ending annual debt data from the most recent year and then calculates the average.
2. The WACC formula discussed above does not include Preferred Stock. Please adjust if preferred stock is considered.
3. (Expected Return of the Market - Risk-Free Rate of Return) is also called market premium. GuruFocus requires market premium to be 6%.
4. GuruFocus uses the latest TTM Interest Expense divided by the latest one-year semi-annual average debt to get the simplified cost of debt.
Related Terms
Lepu Scientech Medical Technology (Shanghai) Co WACC % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lepu Scientech Medical Technology (Shanghai) Co WACC % Chart
Lepu Scientech Medical Technology (Shanghai) Co Annual Data
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lepu Scientech Medical Technology (Shanghai) Co WACC % vs Medical Devices & Instruments Industry
Lepu Scientech Medical Technology (Shanghai) Co WACC % Calculation
The weighted average cost of capital (WACC) is the rate that a company is expected to pay on average to all its security holders to finance its assets. The WACC is commonly referred to as the firm's cost of capital. Generally speaking, a company's assets are financed by debt and equity. WACC is the average of the costs of these sources of financing, each of which is weighted by its respective use in the given situation. By taking a weighted average, we can see how much interest the company has to pay for every dollar it finances.
WACC
=
E
/
(E + D)
*
Cost of Equity
+
D
/
(E + D)
*
Cost of Debt
*
(1 - Tax Rate)
1. Weights:
Generally speaking, a company's assets are financed by debt and equity. We need to calculate the weight of equity and the weight of debt.
The market value of equity (E) is also called "Market Cap". As of today, Lepu Scientech Medical Technology (Shanghai) Co's market capitalization (E) is HK$4198.374 Mil.
The market value of debt is typically difficult to calculate, therefore, GuruFocus uses book value of debt (D) to do the calculation. It is simplified by adding the latest one-year semi-annual average Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation together. As of Dec. 2025, Lepu Scientech Medical Technology (Shanghai) Co's latest one-year semi-annual average Book Value of Debt (D) is HK$2.0313 Mil.
a) weight of equity = E / (E + D) = 4198.374 / (4198.374 + 2.0313) = 0.9995
b) weight of debt = D / (E + D) = 2.0313 / (4198.374 + 2.0313) = 0.0005
2. Cost of Equity:
GuruFocus uses Capital Asset Pricing Model (CAPM) to calculate the required rate of return. The formula is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)
a) GuruFocus uses 10-Year Treasury Constant Maturity Rate as the risk-free rate. It is updated daily. The current risk-free rate is 4.69%. Please go to Economic Indicators page for more information. Please note that we use the 10-Year Treasury Constant Maturity Rate of the country/region where the company is headquartered. If the data for that country/region is not available, then we will use the 10-Year Treasury Constant Maturity Rate of the United States as default.
b) Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. Lepu Scientech Medical Technology (Shanghai) Co's beta is 0.0529.
c) (Expected Return of the Market - Risk-Free Rate of Return) is also called market premium. GuruFocus requires market premium to be 6%.
Cost of Equity = 4.69% + 0.0529 * 6% = 5.0074%
3. Cost of Debt:
GuruFocus uses latest TTM Interest Expense divided by the latest one-year semi-annual average debt to get the simplified cost of debt.
As of Dec. 2025, Lepu Scientech Medical Technology (Shanghai) Co's interest expense (positive number) was HK$0.127 Mil. Its total Book Value of Debt (D) is HK$2.0313 Mil.
Cost of Debt = 0.127 / 2.0313 = 6.2522%.
4. Multiply by one minus TTM Tax Rate:
GuruFocus uses the most recent TTM Tax Expense divided by the most recent TTM Pre-Tax Income to calculate the tax rate. The calculated TTM tax rate is limited to between 0% and 100%. If the calculated tax rate is higher than 100%, it is set to 100%. If the calculated tax rate is less than 0%, it is set to 0%.
The latest calculated TTM Tax Rate = 40.248 / 302.958 = 13.29%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lepu Scientech Medical Technology (Shanghai) Co (HKSE:02291) has a WACC % of 5.01% as of Aug. 20, 2026. The weighted average cost of capital (WACC) is the average rate a company pays to finance assets. View historical data on Lepu Scientech Medical Technology (Shanghai) Co and its competitors. This is 50% below median its historical median of 10.08. Over the past decade, Lepu Scientech Medical Technology (Shanghai) Co's WACC % has ranged from 2.42 to 325.33. According to the industry distribution chart, Lepu Scientech Medical Technology (Shanghai) Co ranks #181 out of 860 companies in the Medical Devices & Instruments industry, placing it in the top 21%.
Is Lepu Scientech Medical Technology (Shanghai) Co's WACC % too high?
Lepu Scientech Medical Technology (Shanghai) Co's current WACC % of 5.01% is 50% below median its 10-year median of 10.08. Over the past 10 years, this metric has ranged from a low of 2.42 to a high of 325.33. The Medical Devices & Instruments industry median WACC % is 9.02. Lepu Scientech Medical Technology (Shanghai) Co's value of 5.01% is 44.4% below this industry median. Based on the distribution chart, Lepu Scientech Medical Technology (Shanghai) Co ranks #181 out of 860 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Lepu Scientech Medical Technology (Shanghai) Co has a GF Score™ of 76/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Lepu Scientech Medical Technology (Shanghai) Co's WACC % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Lepu Scientech Medical Technology (Shanghai) Co ranks #181 out of 860 companies for WACC %. This places Lepu Scientech Medical Technology (Shanghai) Co in the top 21% of its industry — outperforming the majority of peers. The industry median WACC % is 9.02. Lepu Scientech Medical Technology (Shanghai) Co's value of 5.01% is 44.4% below this benchmark. Historically, Lepu Scientech Medical Technology (Shanghai) Co's own WACC % has ranged from 2.42 to 325.33 over the past decade. While the company's 10-year median is 10.08 vs. the industry median of 9.02, Lepu Scientech Medical Technology (Shanghai) Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good WACC % for a Medical Devices & Instruments company?
The median WACC % among Medical Devices & Instruments companies is 9.02, based on 860 companies in the industry. Companies in the top quartile (top 25%) have a WACC % significantly above this median, while those in the bottom quartile fall well below. However, WACC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lepu Scientech Medical Technology (Shanghai) Co's current WACC % of 5.01% is 44.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high WACC % mean?
A high WACC % can signal that a stock is expensive relative to its fundamentals. The weighted average cost of capital (WACC) is the average rate a company pays to finance assets. View historical data on Lepu Scientech Medical Technology (Shanghai) Co and its competitors. For the Medical Devices & Instruments industry, the median WACC % is 9.02 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lepu Scientech Medical Technology (Shanghai) Co's current WACC % is 5.01%, which is 50% below median its own 10-year median of 10.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lepu Scientech Medical Technology (Shanghai) Co stock overvalued right now?
Based on GuruFocus' analysis, Lepu Scientech Medical Technology (Shanghai) Co (HKSE:02291) is currently considered Significantly Undervalued. The stock's GF Value™ is HK$44.29, compared to a current price of HK$12.18 — trading 72.5% below its estimated fair value. The current WACC % is 5.01%, which is 50% below median its 10-year median of 10.08 and 44.4% below the Medical Devices & Instruments industry median of 9.02. Lepu Scientech Medical Technology (Shanghai) Co's overall GF Score™ is 76/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is WACC % calculated?
WACC % is calculated from a company's financial statements. For Lepu Scientech Medical Technology (Shanghai) Co (HKSE:02291), the current WACC % is 5.01% as of Aug. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lepu Scientech Medical Technology (Shanghai) Co (HKSE:02291) Overvalued in 2026?
Based on GuruFocus' analysis, Lepu Scientech Medical Technology (Shanghai) Co stock appears to be undervalued.
The current stock price of HK$12.18 is trading 72.5% below its estimated GF Value™ of HK$44.29.
GuruFocus considers Lepu Scientech Medical Technology (Shanghai) Co to be Significantly Undervalued.
Key valuation signals for HKSE:02291:
WACC %: 5.01% (50% below median its 10-year median of 10.08)
GF Value™: HK$44.29 vs. price of HK$12.18 (72.5% below fair value)
Industry Position: 44.4% below the Medical Devices & Instruments median (#181 of 860)
No single metric tells the full story. See the HKSE:02291 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lepu Scientech Medical Technology (Shanghai) Co Ltd is focused on the research and development, manufacture, and commercialization of heart disease interventional medical devices. The reporting segments of the Group are as follows: The Occluder business segment and The heart valve business segment. The company generates majority of its revenue from the Occluder segment which is engaged in the research and development, manufacturing and sales of interventional treatment series occluders for the defective congenital heart disease.
76GF Score
Get the complete analysis for HKSE:02291
WACC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02291 has been successfully added to your 
